Quarterly report pursuant to Section 13 or 15(d)

Note 12 - Segment Information (Tables)

v3.10.0.1
Note 12 - Segment Information (Tables)
 6 Months Ended
Dec. 31, 2018
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
   
Quarter Ended
    
Six Months Ended
  
   
December 31,
    
December 31,
  
   
2018
    
2017
    
2018
    
2017
  
Net sales:
                                
Protein Sciences
   $
135,462
     $
117,142
     $
261,852
     $
225,255
  
Diagnostics and Genomics
    
39,263
      
37,086
      
76,010
      
73,675
  
Intersegment
    
(215
 )    
(75
)
    
(382
 )    
(164
)
Consolidated net sales
   $
174,510
     $
154,153
     $
337,480
     $
298,766
  
Operating income:
                                
Protein Sciences
   $
58,951
     $
50,218
     $
113,565
     $
96,427
  
Diagnostics and Genomics
    
(1,054
 )    
5,888
      
1,482
      
13,167
  
Segment operating income
   $
57,897
     $
56,106
     $
115,047
     $
109,594
  
Costs recognized on sale of acquired inventory
    
(935
 )    
(264
)
    
(1,869
 )    
(582
)
Amortization of acquisition related intangible assets
    
(15,002
 )    
(11,296
)
    
(29,278
 )    
(22,675
)
Acquisition related expenses
    
(348
 )    
(13,150
)
    
(2,973
 )    
(22,683
)
Stock based compensation
    
(6,861
 )    
(5,044
)
    
(18,426
 )    
(8,839
)
Corporate general, selling, and administrative expenses
    
(1,148
 )    
(2,204
)
    
(3,137
 )    
(4,636
)
Consolidated operating income
   $
33,603
     $
24,148
     $
59,364
     $
50,179